×
About 4,285 results

ALLMedicine™ Medulloblastoma Center

Research & Reviews  1,612 results

Genetic Markers as Predictors for Response to Treatment and Possible Therapeutic Target...
https://doi.org/10.2174/1871527321666220509141030
CNS & Neurological Disorders Drug Targets; Pérez-Pineda PL, Ortiz-Butrón R et. al.

May 18th, 2022 - Medulloblastomas (MB) are the most common malignant brain tumors in the pediatric age. In 2021, WHO categorized medulloblastomas into two groups: molecularly defined and histologically defined medulloblastomas. Molecularly defined medulloblastomas...

Molecular pathological insights reveal a high number of unfavorable risk patients among...
https://doi.org/10.1002/pbc.29736
Pediatric Blood & Cancer; Niehusmann P, Stensvold E et. al.

May 17th, 2022 - An unexplained regional difference in survival was observed in previous publications on outcome for children treated for medulloblastoma and supratentorial primitive neuroectodermal tumor (CNS-PNET) in Norway. We aimed now to reevaluate and perfor...

Possible mechanisms and biomarkers of resistance to vismodegib in SHH medulloblastoma.
https://doi.org/10.1093/neuonc/noac061
Neuro-oncology Roesler R, de Farias CB et. al.

May 14th, 2022 - Possible mechanisms and biomarkers of resistance to vismodegib in SHH medulloblastoma.|2022|Roesler R,de Farias CB,Brunetto AT,Gregianin L,Jaeger M,|

A case of postoperative cerebellar mutism with hyperphagia in a child following gross t...
https://doi.org/10.1007/s00381-022-05520-9 10.3171/jns.1984.61.4.0657 10.3171/ped.2006.105.6.444 10.1159/000120499 10.4103/0028-3886.115086 10.1073/pnas.96.8.4569 10.1016/j.neuron.2017.06.014 10.1002/jnr.21420 10.1046/j.0022-7722.2003.00055.x 10.1016/S0149-7634(02)00014-3 10.1016/S0899-9007(97)00400-0 10.1080/14734220310016187 10.1007/BF00326585 10.1007/s12311-018-0938-1 10.1016/j.neulet.2018.04.024 10.1007/s00429-019-01985-8 10.1016/j.neures.2003.12.009 10.1016/j.neulet.2004.07.072 10.1016/j.brainresrev.2006.01.003 10.1007/s10571-007-9236-z 10.1186/s40673-016-0047-1 10.1007/s00429-016-1257-2 10.1016/j.cortex.2009.10.007 10.1002/jnr.21059 10.1007/s00381-005-1223-4 10.3171/2013.8.PEDS13168 10.1007/s00381-019-04229-6 10.3174/ajnr.A1821 10.1007/s00381-019-04253-6 10.3171/jns.1995.83.3.0467 10.1007/BF01406016 10.1186/s12885-017-3416-0 10.1227/00006123-198411000-00014 10.1001/archneur.1985.04060070091023 10.1001/archneur.1986.00520040003002 10.1007/BF00706739 10.1080/02687038908248972 10.3171/jns.1990.72.6.0959 10.1016/0090-3019(91)90094-P 10.1159/000120595 10.1111/j.1469-8749.1992.tb11424.x 10.1055/s-2008-1071330 10.1002/jso.2930550214 10.1007/BF01401456 10.3171/jns.1994.81.1.0115 10.1007/BF00301168 10.1212/WNL.44.11.2040 10.1007/BF00301766 10.1227/00006123-199511000-00006 10.1177/104345429501200402 10.1097/00006123-199601000-00015 10.1097/00006123-199802000-00027 10.1159/000072468 10.1007/s00415-004-0472-6 10.1016/j.pediatrneurol.2004.07.014 10.3171/jns.2006.104.2.329
Child's Nervous System : ChNS : Official Journal of the I... Alharbi S, Bawazir M et. al.

May 11th, 2022 - Cerebellar mutism syndrome is a well-known complication following posterior fossa tumor resection. Its incidence is markedly increased among patients with medulloblastoma. Patients typically present with an inability to communicate verbally due to...

Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
https://clinicaltrials.gov/ct2/show/NCT04023669

May 6th, 2022 - Participants will be stratified by the biological characteristics of their tumor to one of two treatment strata: STRATUM A Combination Treatment: prexasertib and cyclophosphamide Patient population: Participants with recurrent/refractory Group 3 a...

see more →

Guidelines  2 results

SEOM clinical guideline for management of adult medulloblastoma (2020).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057961
Clinical & Translational Oncology : Official Publication ... Luque R, Benavides M et. al.

Apr 2nd, 2021 - Recent advances in molecular profiling, have reclassified medulloblastoma, an undifferentiated tumor of the posterior fossa, in at least four diseases, each one with differences in prognosis, epidemiology and sensibility to different treatments. T...

SIOP PODC adapted treatment recommendations for standard-risk medulloblastoma in low an...
https://doi.org/10.1002/pbc.25313
Pediatric Blood & Cancer; Parkes J, Hendricks M et. al.

Nov 25th, 2014 - Effective treatment of children with medulloblastoma requires a functioning multi-disciplinary team with adequate neurosurgical, neuroradiological, pathological, radiotherapy and chemotherapy facilities and personnel. In addition the treating cent...

see more →

Drugs  10 results see all →

Clinicaltrials.gov  45 results

Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
https://clinicaltrials.gov/ct2/show/NCT04023669

May 6th, 2022 - Participants will be stratified by the biological characteristics of their tumor to one of two treatment strata: STRATUM A Combination Treatment: prexasertib and cyclophosphamide Patient population: Participants with recurrent/refractory Group 3 a...

Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma
https://clinicaltrials.gov/ct2/show/NCT04402073

May 5th, 2022 - Medulloblastoma is a rare brain malignancy, mainly affecting children. Treatment of this rapidly growing tumor begins with maximal surgical removal plus radiation and chemotherapy. Treatment toxicity is high. Post-pubertal and pediatric medullobla...

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors or Meningiomas Expressing SST2A
https://clinicaltrials.gov/ct2/show/NCT05278208

Apr 28th, 2022 - Somatostatin receptors regulate cell growth through downstream modulation of both proliferation and apoptosis signaling pathways, and thus represent a potential therapeutic target. Lutathera (Lutetium [Lu]177 Dotatate) is a radionuclide therapy wh...

Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
https://clinicaltrials.gov/ct2/show/NCT00601003

Apr 28th, 2022 - This study is being done to test the effect of a drug, nifurtimox, against neuroblastoma and medulloblastoma in children. Nifurtimox is a drug that has been used in South America for many years to treat a parasitic disease known as Chagas Disease....

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
https://clinicaltrials.gov/ct2/show/NCT05096481

Apr 28th, 2022 - This phase II clinical trial will have 3 strata in order to assess the efficacy of a highly immunogenic CMV-directed peptide vaccines in children with (1) recurrent medulloblastoma (rMB), (2) newly-diagnosed high-grade gliomas (HGG) and (3) newly-...

see more →

News  41 results

FDA Accepts NDA Resubmission for Pedmark in Prevention of Platinum-Induced Ototoxicity in Solid Tumors
https://www.onclive.com/view/fda-accepts-nda-resubmission-for-pedmark-in-prevention-of-platinum-induced-ototoxicity-in-solid-tumors

Apr 28th, 2022 - The FDA has accepted for filing the new drug application (NDA) resubmission for a unique formulation of sodium thiosulfate (Pedmark) for the prevention of platinum-induced ototoxicity in patients between the ages of 1 month and 18 years who have l...

NDA Resubmitted to FDA for Pedmark in Prevention of Cisplatin-Induced Ototoxicity in Solid Tumors
https://www.onclive.com/view/nda-resubmitted-to-fda-for-pedmark-in-prevention-of-cisplatin-induced-ototoxicity-in-solid-tumors

Apr 28th, 2022 - The new drug application seeking the approval of a unique formulation of sodium thiosulfate (Pedmark) for the prevention of ototoxicity induced by cisplatin chemotherapy in patients aged 1 month to less than 18 years of age with localized, nonmeta...

New ASTRO President Calls Attention to In-Person Meetings, Remaining Challenges, and Ongoing Research in Radiation Oncology
https://www.onclive.com/view/new-astro-president-calls-attention-to-in-person-meetings-remaining-challenges-and-ongoing-research-in-radiation-oncology

Nov 24th, 2021 - Following the period of virtual medical meetings due to the COVID-19 pandemic, the field of radiation oncology is navigating the world of hybrid conferences to continue pushing the paradigm forward, said Jeff M. Michalski, MD, MBA, FASTRO, who add...

Dr. Cohen Addresses the Role of the Hedgehog Pathway
https://www.onclive.com/view/dr-cohen-addresses-the-role-of-the-hedgehog-pathway

Oct 6th, 2021 - Deirdre J. Cohen, MD, Assistant Professor, Department of Medicine, Clinical Cancer Center, NYU Medical Oncology Associates, at the Cancer Institute at NYU Langone Medical Center, discusses the normal role of the hedgehog signaling pathway and pote...

Models Pave the Way for Improved Outcomes in Medulloblastoma
https://www.onclive.com/view/models-pave-the-way-for-improved-outcomes-in-medulloblastoma

Oct 6th, 2021 - Robert Wechsler-Reya, PhD The management of medulloblastoma (MB), the most common malignant brain cancer in children, has not changed in decades but breakthroughs are on the horizon. Only 5 years after the definition of the molecular subgroups...

see more →

Patient Education  4 results see all →